Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Leiden, the Netherlands.
| Revenue (TTM) | $366.48M |
| Gross Profit (TTM) | $317.08M |
| EBITDA | $32.88M |
| Operating Margin | 1.46% |
| Return on Equity | 3.65% |
| Return on Assets | 3.47% |
| Revenue/Share (TTM) | $5.22 |
| Book Value | $3.61 |
| Price-to-Book | 3.08 |
| Price-to-Sales (TTM) | 2.26 |
| EV/Revenue | 2.091 |
| EV/EBITDA | 19.69 |
| Quarterly Earnings Growth (YoY) | -62.90% |
| Quarterly Revenue Growth (YoY) | -3.20% |
| Shares Outstanding | $70.78M |
| Float | $69.66M |
| % Insiders | 0.00% |
| % Institutions | 0.14% |
Volatility is currently contracting
Pharming Group told investors to expect up to $425 million in 2026 revenue. The Company now expects as little as $375 million -- and the stock lost 22% in a single session.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Pharming Group N.V. (“Pharming” or the “Company”) (NASDAQ: PHAR) on behalf of investors concerning the Company's possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON PHARMING GROUP N.V. (PHAR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.What Is The Investigation About? On July 30, 2026, the Company reported second quarter earnings, inc.
Pharming Group shares fell 22% on July 30, 2026 after the Company reported a Q2 revenue decline and reduced its full-year 2026 outlook by roughly $30 million. Levi & Korsinsky is investigating potential securities law violations on behalf of PHAR investors Pharming Group shares fell 22% on July 30, 2026 after the Company reported a Q2 revenue decline and reduced its full-year 2026 outlook by roughly $30 million. Levi & Korsinsky is investigating potential securities law violations on behalf of PHAR investors
Pharming Group's legacy product RUCONEST posted a 10% year-over-year sales decline in Q2 2026 -- and PHAR shares fell 22% the day it was reported. Levi & Korsinsky is investigating potential securities law violations on behalf of PHAR shareholders.
Pharming Group N.V. (PHAR) Q2 2026 Earnings Call Transcript
Pharming Group NASDAQ: PHAR reported second-quarter revenue of $90.2 million, down 3% from a year earlier, as growth from its Joenja treatment partly offset lower sales of hereditary angioedema therapy RUCONEST. The company reduced its full-year revenue outlook by $30 million but said it expects RUCONEST sales to stabilize and return to growth during the second half of 2026.
Pharming Group NASDAQ: PHAR executives said first-quarter 2026 results reflected an expected decline in RUCONEST revenue tied largely to specialty pharmacy inventory movements and the company's planned exit from certain non-U.S. markets, while Joenja continued to post strong growth and the company advanced regulatory and clinical milestones across its pipeline. Get Pharming Group alerts:Sign UpRUCONEST revenue declined as inventory dynamics played out CEO Fabrice Chouraqui said quarterly revenue fell primarily due to RUCONEST, a decline he said was “largely expected due to inventory drawdown at specialty pharmacy,” which the company previously discussed on its fourth-quarter 2025 call.
Pharming Group N.V. (PHAR) Q1 2026 Earnings Call Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PHAR and any ticker you trade — then tracks every position and per-strategy win rate.
